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Abstract 
 
Colorectal cancer (CRC) is a common cancer and the second leading cause of cancer 
death in the Western world. It is the commonest cancer among men and the third most common 
cancer among women in Malaysia. Previous studies have reported 43% of colorectal cancers 
have KRAS2 gene mutation. KRAS2 (Kirsten-ras) gene is oncogene group which is located on 
chromosome 12p12 and has an important role in the Ras/MAPK signaling pathway. Its 
mutations on codon 12 will raise 30% the risk of recurrence or death, and are correlated 50% to 
increasing risks of recurrence or death in Duke’s C colorectal cancers. The aim of this study 
was to analyze KRAS2 gene mutation in Malaysian Colorectal cancer patients.  
Tumor and normal tissues were collected from 75 patients admitted to UKM Medical 
Center. DNA from 25 mg tissue was extracted by QIAamp DNA kit. KRAS2 gene was amplified 
using PCR and the mutation was detected using dHPLC and Sequencing.  
Seventy five patients with colorectal cancer involved in this study; i.e. 53.3% (n=40) females 
and 46.7% (n=35) males. Most of the patients are Chinese (62.7%) compared to Malays 
(33.3%) and Indian (2.7%). Mutation of KRAS2 gene was detected in 46.7% (35/75) of the CRC 
patients. On affected male mostly diagnosed at younger age, while on female at older age with 
significant correlation p=0.046. A significant correlation was found in patients with familial 
history and KRAS2 gene mutation status (p=0.003) and early age of onset ≤50 years old 
(p=0.022).  
The determination of KRAS2 gene status in colorectal cancer patients is important 
especially for colorectal cancer in early age of affected male, and also in familial cases. Familial 
cancer screening of younger patients is needed for early management and counselling 
strategies.  
 
Keywords: KRAS2 gene mutation, colorectal cancer 
 
 
 
 
